Liquidia Corp (LQDA)
Liquidia is a biopharmaceutical company that sells YUTREPIA, an inhaled treprostinil treatment for pulmonary arterial hypertension. It last closed at $56.73 on Nov 17, up 0.64% on the day. LQDA last reported earnings on Tue, Nov 10, 2026. The average 12-month price target from 7 analysts is $63.29 (+11.6% from the last close), with a high of $87.00 and a low of $40.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (6 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 9 whale options trades in LQDA, 44% of them bullish and 56% bearish. In the past 30 days there were 2 dark pool prints totaling $2.3M, the largest $1.5M.
Key Stats
Last 12 monthsNot reported for this period.
From LQDA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 7 analysts who set a price target on LQDA in the past 90 days. The average target is $63.29, with a high of $87.00 and a low of $40.00, compared with the last close of $56.73.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 13 | HC Wainwright & Co. | Assumed coverage | Buy | $76 |
| Nov 11 | Wells Fargo | Target raised | Hold | $33 → $40 |
| Nov 11 | Needham | Target raised | Buy | $58 → $66 |
| Nov 10 | Jefferies | Maintained | Buy | $62 |
| Nov 10 | BTIG | Target raised | Buy | $70 → $87 |
Technical Analysis
The stock is 16% above its 20 day and 15% above its 50 day average. It is 3% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 65), near overbought. The nearest support is the Pivot at $56.24, and the nearest resistance the Pivot R1 at $57.69.
| RSI (14) | 65.36 | Strong, overbought above 70 | Neutral |
| MACD | 3.24 | Above its signal line | Bullish |
| Stochastic | 85.2 | Near the top of its range | Overbought |
| ADX (14) | 30.8 | Trending up | |
| Williams %R | -15.4 | Oversold below −80, overbought above −20 | Overbought |
| CCI (20) | 122.2 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +34.4% | Change over 10 sessions | Bullish |
| ATR (14) | $3.73 | Typical daily range, 6.6% of price |
| RSI (14) | 51.31 | Middle of its range | Neutral |
| MACD | -2.59 | Below its signal line | Bearish |
| Stochastic | 47.4 | Middle of its range | Neutral |
| ADX (14) | 25.1 | Trending down | |
| Williams %R | -38.1 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -25.0 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −15.0% | Change over 10 sessions | Bearish |
| ATR (14) | $10.08 | Typical daily range, 17.8% of price |
What happened before
See how LQDA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How LQDA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in LQDA in the last 90 days.
Dark Pool
30DLQDA Institutional Ownership
Full report →- ●179 buying vs 188 selling
- ▲Held by funds +2.9 pts
- ▼Funds holding -35
- ▲Superinvestors: 2 added, 0 cut
- ●Put/call 1.57 to 1.62
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 305 | 340 | −10.3% |
| In funds' top 10 | 8 | 13 | −38.5% |
| Held by funds | 83.6% | 80.7% | +2.9 pts |
| New / increased | 63 / 116 | 127 / 103 | −22.2% |
| Reduced / sold out | 93 / 95 | 82 / 34 | +62.1% |
| Put/call ratio | 1.62 | 1.57 | +3.4% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LQDA is in one of them and how their past LQDA trades turned out.
LQDA News Tone and Price
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LQDA in an article yet. Here's the latest on the wider market.
LQDA Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Donald J TrumpExecutive branch | Sell | $15K – $50K | Aug 31, 2026 | Sep 22, 2026 | 22 d |
| Donald J TrumpExecutive branch | Sell | $50K – $100K | Jul 29, 2026 | Sep 22, 2026 | 55 d |
| Donald J TrumpExecutive branch | Sell | $1K – $15K | Jul 8, 2026 | Sep 22, 2026 | 76 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Liquidia
Liquidia is a biopharmaceutical company based in Morrisville, North Carolina, that develops and sells medicines for lung and blood vessel diseases. Its main product is YUTREPIA, an inhaled treprostinil powder used to treat pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease. The company also shares profits from a generic treprostinil injection sold in the United States and is developing other treatments, including for pulmonary hypertension linked to COPD. Its customers include healthcare providers who treat these patients and the organizations that distribute and pay for these medicines.
- Headquarters
- Morrisville, NC


